MD3328888T2 - Anticorpi anti-PSMA, molecule de legare a antigenelor bispecifice care leagă PSMA și CD3 și utilizările acestora - Google Patents
Anticorpi anti-PSMA, molecule de legare a antigenelor bispecifice care leagă PSMA și CD3 și utilizările acestoraInfo
- Publication number
- MD3328888T2 MD3328888T2 MDE20180558T MDE20180558T MD3328888T2 MD 3328888 T2 MD3328888 T2 MD 3328888T2 MD E20180558 T MDE20180558 T MD E20180558T MD E20180558 T MDE20180558 T MD E20180558T MD 3328888 T2 MD3328888 T2 MD 3328888T2
- Authority
- MD
- Moldova
- Prior art keywords
- psma
- antibodies
- bind
- present
- antigen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Pregnancy & Childbirth (AREA)
- Cell Biology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Prezenta invenţie se referă la anticorpi care se leagă la antigenul specific prostatic (PSMA), la anticorpi bispecifici care se leagă la PSMA şi CD3, şi la metode de utilizare a acestora. Conform unor anumite variante de realizare, anticorpii prezentei invenţii leagă PSMA uman cu afinitate mare şi leagă CD3 inducând proliferarea celulelor T umane. Prezenta descriere include anticorpi care leagă PSMA şi CD3 şi induc uciderea mediată de celule T a celulelor tumorale, care exprimă PSMA. Conform unor anumite variante de realizare, prezenta invenţie se referă la molecule bispecifice de legare a antigenului, care cuprind un prim domeniu de legare a antigenului, care leagă în mod specific CD3 uman, şi o a doua moleculă de legare a antigenului, care leagă în mod specific PSMA uman. În unele variante de realizare moleculele bispecifice de legare a antigenului din prezenta invenţie sunt capabile să inhibe creşterea tumorilor de prostată, care exprimă PSMA. Anticorpii şi moleculele bispecifice de legare la antigen, conform prezentei invenţii, sunt utile pentru tratamentul bolilor şi tulburărilor în care un răspuns imunitar ţintit indus sau amplificat este dezirabil şi/sau terapeutic benefic. De exemplu, anticorpii, conform prezentei invenţii, sunt utili pentru tratamentul diferitor tipuri de cancer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562199823P | 2015-07-31 | 2015-07-31 | |
US201562222590P | 2015-09-23 | 2015-09-23 | |
US201662351823P | 2016-06-17 | 2016-06-17 | |
PCT/US2016/044732 WO2017023761A1 (en) | 2015-07-31 | 2016-07-29 | Anti-psma antibodies, bispecific antigen-binding molecules that bind psma and cd3, and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MD3328888T2 true MD3328888T2 (ro) | 2023-04-30 |
Family
ID=56610023
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MDE20180558T MD3328888T2 (ro) | 2015-07-31 | 2016-07-29 | Anticorpi anti-PSMA, molecule de legare a antigenelor bispecifice care leagă PSMA și CD3 și utilizările acestora |
Country Status (24)
Country | Link |
---|---|
US (3) | US10179819B2 (ro) |
EP (2) | EP3328888B1 (ro) |
JP (2) | JP6975707B2 (ro) |
KR (1) | KR20180042272A (ro) |
CN (1) | CN108137700B (ro) |
AR (1) | AR106570A1 (ro) |
AU (1) | AU2016302928B2 (ro) |
CA (1) | CA2994245A1 (ro) |
DK (1) | DK3328888T3 (ro) |
EA (1) | EA038603B1 (ro) |
ES (1) | ES2935120T3 (ro) |
FI (1) | FI3328888T3 (ro) |
HK (1) | HK1255971A1 (ro) |
HR (1) | HRP20230237T1 (ro) |
HU (1) | HUE061419T2 (ro) |
JO (1) | JOP20160154B1 (ro) |
LT (1) | LT3328888T (ro) |
MD (1) | MD3328888T2 (ro) |
PL (1) | PL3328888T3 (ro) |
PT (1) | PT3328888T (ro) |
RS (1) | RS63991B1 (ro) |
SI (1) | SI3328888T1 (ro) |
TW (1) | TWI728990B (ro) |
WO (1) | WO2017023761A1 (ro) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014110601A1 (en) | 2013-01-14 | 2014-07-17 | Xencor, Inc. | Novel heterodimeric proteins |
TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
US10858417B2 (en) | 2013-03-15 | 2020-12-08 | Xencor, Inc. | Heterodimeric proteins |
US10259887B2 (en) | 2014-11-26 | 2019-04-16 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and tumor antigens |
BR112017011092A2 (pt) | 2014-11-26 | 2017-12-26 | Xencor Inc | anticorpos heterodiméricos que ligam cd3 e antígenos de tumor |
PL3277725T3 (pl) | 2015-03-30 | 2021-06-14 | Regeneron Pharmaceuticals, Inc. | Regiony stałe łańcucha ciężkiego o zmniejszonym wiązaniu do receptorów Fc gamma |
EP4129327A1 (en) | 2015-08-28 | 2023-02-08 | Amunix Pharmaceuticals, Inc. | Chimeric polypeptide assembly and methods of making and using the same |
SI3353212T1 (sl) * | 2015-09-23 | 2022-01-31 | Regeneron Pharmaceuticals, Inc., | Optimizirana bispecifična protitelesa proti-CD3 in njihove uporabe |
JP7323102B2 (ja) | 2016-04-13 | 2023-08-08 | オリマブス リミテッド | 抗psma抗体およびその使用 |
CA3050085A1 (en) | 2017-01-20 | 2018-07-26 | Juno Therapeutics Gmbh | Cell surface conjugates and related cell compositions and methods |
CN110730908A (zh) | 2017-04-07 | 2020-01-24 | 朱诺治疗学股份有限公司 | 表达前列腺特异性膜抗原(psma)或其修饰形式的工程化细胞及相关方法 |
WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
JP7247110B2 (ja) | 2017-06-05 | 2023-03-28 | ヌマブ セラピューティクス アクチェンゲゼルシャフト | 新規抗cd3抗体 |
EP3688029A1 (en) * | 2017-09-29 | 2020-08-05 | Regeneron Pharmaceuticals, Inc. | Bispecific antigen-binding molecules that bind a staphylococcus target antigen and a complement component and uses thereof |
JOP20200303A1 (ar) * | 2018-05-24 | 2020-11-23 | Janssen Biotech Inc | عوامل ربط psma واستخداماتها |
CA3104098A1 (en) * | 2018-06-21 | 2019-12-26 | Regeneron Pharmaceuticals, Inc. | Bispecific anti-psma x anti-cd28 antibodies and uses thereof |
WO2020047389A1 (en) | 2018-08-31 | 2020-03-05 | Regeneron Pharmaceuticals, Inc. | Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies |
EP4270009A3 (en) | 2018-10-31 | 2024-01-17 | Regeneron Pharmaceuticals, Inc. | Method and system of identifying and quantifying a protein |
US11249089B2 (en) | 2018-12-12 | 2022-02-15 | Regeneron Pharmaceuticals, Inc. | System and method of analysis of a protein using liquid chromatography-mass spectrometry |
JP2022530301A (ja) * | 2019-02-22 | 2022-06-29 | 武▲漢▼友芝友生物制▲薬▼有限公司 | Cd3抗原結合性断片及びその使用 |
EP3947440A1 (en) * | 2019-03-29 | 2022-02-09 | F. Hoffmann-La Roche AG | Method for generating avid-binding multispecific antibodies |
BR112021020873A2 (pt) * | 2019-04-19 | 2022-04-19 | Janssen Biotech Inc | Métodos para tratamento de câncer renal com um anticorpo anti-psma/cd3 |
MA55717A (fr) * | 2019-04-19 | 2022-02-23 | Janssen Biotech Inc | Méthodes de traitement du cancer de la prostate avec un anticorps anti-psma/cd3 |
CR20210622A (es) | 2019-06-14 | 2022-06-27 | Teneobio Inc | Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3 |
CA3139827A1 (en) * | 2019-06-21 | 2020-12-24 | Regeneron Pharmaceuticals, Inc. | Use of bispecific antigen-binding molecules that bind psma and cd3 in combination with 4-1bb co-stimulation |
MX2021015669A (es) * | 2019-07-02 | 2022-04-18 | Telix Int Pty Ltd | Anticuerpos para la unión a psma. |
WO2021019301A2 (en) * | 2019-07-26 | 2021-02-04 | Aratinga.Bio Aci | Anti-cd3 aptamers for use in cell targeting and labeling |
CN115023439A (zh) * | 2019-09-06 | 2022-09-06 | 西福根有限公司 | 抗cd73抗体 |
US20230071763A1 (en) * | 2020-01-06 | 2023-03-09 | Cytomx Therapeutics, Inc. | Auristatin-related compounds, conjugated auristatin-related compounds, and methods of use thereof |
KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
CN111303288B (zh) * | 2020-03-04 | 2020-12-25 | 和铂医药(苏州)有限公司 | 一种分离的结合抗原psma的蛋白及其用途 |
WO2021231976A1 (en) * | 2020-05-14 | 2021-11-18 | Xencor, Inc. | Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3 |
JP2023542257A (ja) | 2020-09-16 | 2023-10-05 | アムジェン インコーポレイテッド | 癌の治療のために二重特異性t細胞誘導分子の治療用量を投与する方法 |
US11555078B2 (en) | 2020-12-09 | 2023-01-17 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting PSMA and effector cell antigens |
WO2022162518A2 (en) * | 2021-01-28 | 2022-08-04 | Janssen Biotech, Inc. | Psma binding proteins and uses thereof |
MX2023008949A (es) | 2021-01-28 | 2023-10-23 | Regeneron Pharma | Composiciones y metodos para tratar el sindrome de liberacion de citocinas. |
KR20230156079A (ko) | 2021-03-09 | 2023-11-13 | 젠코어 인코포레이티드 | Cd3과 cldn6에 결합하는 이종이량체 항체 |
US11859012B2 (en) | 2021-03-10 | 2024-01-02 | Xencor, Inc. | Heterodimeric antibodies that bind CD3 and GPC3 |
EP4330281A1 (en) | 2021-04-29 | 2024-03-06 | Amgen Inc. | Methods for reducing low molecular weight species of recombinantly-produced proteins |
WO2023164510A1 (en) | 2022-02-23 | 2023-08-31 | Xencor, Inc. | Anti-cd28 x anti-psma antibodies |
WO2023183231A1 (en) | 2022-03-21 | 2023-09-28 | Amgen Inc. | Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer |
US20230357446A1 (en) | 2022-04-11 | 2023-11-09 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
WO2023224912A1 (en) | 2022-05-16 | 2023-11-23 | Regeneron Pharmaceuticals, Inc. | Methods of treating metastatic castration-resistant prostate cancer with bispecific anti-psma x anti-cd3 antibodies alone or in combination with anti-pd-1 antibodies |
WO2024035953A2 (en) * | 2022-08-11 | 2024-02-15 | Adicet Therapeutics, Inc. | Affinity binding entities directed to psma and methods of use thereof |
WO2024123698A1 (en) | 2022-12-08 | 2024-06-13 | Regeneron Pharmaceuticals, Inc. | Methods to characterizing a fragment crystallizable domain of a bispecific antibody |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1017981A (en) | 1911-05-29 | 1912-02-20 | Auguste Arsene Lemetre | Electroplating with zinc. |
IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
US5162504A (en) | 1988-06-03 | 1992-11-10 | Cytogen Corporation | Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients |
DK0590058T3 (da) | 1991-06-14 | 2004-03-29 | Genentech Inc | Humaniseret heregulin-antistof |
US7105159B1 (en) | 1992-11-05 | 2006-09-12 | Sloan-Kettering Institute For Cancer Research | Antibodies to prostate-specific membrane antigen |
US6962981B1 (en) | 1996-03-25 | 2005-11-08 | Medarex, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
ATE318147T1 (de) | 1996-03-25 | 2006-03-15 | Medarex Inc | Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen |
US6150508A (en) | 1996-03-25 | 2000-11-21 | Northwest Biotherapeutics, Inc. | Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen |
US6107090A (en) | 1996-05-06 | 2000-08-22 | Cornell Research Foundation, Inc. | Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains |
US6136311A (en) | 1996-05-06 | 2000-10-24 | Cornell Research Foundation, Inc. | Treatment and diagnosis of cancer |
US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
US7514078B2 (en) | 2001-06-01 | 2009-04-07 | Cornell Research Foundation, Inc. | Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies |
WO2002098897A2 (en) | 2001-06-01 | 2002-12-12 | Cornell Research Foundation, Inc. | Modified antibodies to prostate-specific membrane antigen and uses thereof |
US7666414B2 (en) | 2001-06-01 | 2010-02-23 | Cornell Research Foundation, Inc. | Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen |
EP2360169B1 (en) | 2001-10-23 | 2015-10-14 | Psma Development Company, L.L.C. | PSMA antibodies |
WO2004106380A2 (en) | 2003-05-31 | 2004-12-09 | Micromet Ag | Human-anti-human cd3 binding molecules |
JP5848861B2 (ja) | 2004-04-20 | 2016-01-27 | ジェンマブ エー/エスGenmab A/S | Cd20に対するヒトモノクローナル抗体 |
AU2006214031A1 (en) | 2005-02-18 | 2006-08-24 | Medarex, Inc. | Human monoclonal antibodies to prostate specific membrane antigen (PSMA) |
SI2041177T1 (sl) | 2006-06-02 | 2012-03-30 | Regeneron Pharma | Visoko afinitetna protitelesa za humani IL receptor |
RU2448979C2 (ru) | 2006-12-14 | 2012-04-27 | Ридженерон Фармасьютикалз, Инк. | Антитела человека к дельта-подобному лиганду-4 человека |
JP6126782B2 (ja) | 2008-10-01 | 2017-05-10 | アムゲン リサーチ (ミュンヘン) ゲーエムベーハー | 異種間特異的psma×cd3二重特異性単鎖抗体 |
TWI507525B (zh) | 2009-06-26 | 2015-11-11 | Regeneron Pharma | 具天然免疫球蛋白形式之易分離的雙專一性抗體 |
JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
RS59001B1 (sr) | 2010-02-08 | 2019-08-30 | Regeneron Pharma | Miš sa zajedničkim lakim lancem |
TWI653333B (zh) * | 2010-04-01 | 2019-03-11 | 安進研究(慕尼黑)有限責任公司 | 跨物種專一性之PSMAxCD3雙專一性單鏈抗體 |
WO2013145714A1 (ja) | 2012-03-30 | 2013-10-03 | 川崎重工業株式会社 | 水力発電装置 |
AU2013249267A1 (en) * | 2012-04-20 | 2014-10-23 | Aptevo Research And Development Llc | CD3 binding polypeptides |
JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
TWI682941B (zh) | 2013-02-01 | 2020-01-21 | 美商再生元醫藥公司 | 含嵌合恆定區之抗體 |
TWI701042B (zh) * | 2014-03-19 | 2020-08-11 | 美商再生元醫藥公司 | 用於腫瘤治療之方法及抗體組成物 |
-
2016
- 2016-07-25 JO JOP/2016/0154A patent/JOP20160154B1/ar active
- 2016-07-28 TW TW105123831A patent/TWI728990B/zh active
- 2016-07-29 PL PL16748023.5T patent/PL3328888T3/pl unknown
- 2016-07-29 WO PCT/US2016/044732 patent/WO2017023761A1/en active Application Filing
- 2016-07-29 KR KR1020187005964A patent/KR20180042272A/ko not_active Application Discontinuation
- 2016-07-29 AU AU2016302928A patent/AU2016302928B2/en active Active
- 2016-07-29 EP EP16748023.5A patent/EP3328888B1/en active Active
- 2016-07-29 ES ES16748023T patent/ES2935120T3/es active Active
- 2016-07-29 SI SI201631655T patent/SI3328888T1/sl unknown
- 2016-07-29 CN CN201680058001.9A patent/CN108137700B/zh active Active
- 2016-07-29 HR HRP20230237TT patent/HRP20230237T1/hr unknown
- 2016-07-29 DK DK16748023.5T patent/DK3328888T3/da active
- 2016-07-29 FI FIEP16748023.5T patent/FI3328888T3/fi active
- 2016-07-29 LT LTEPPCT/US2016/044732T patent/LT3328888T/lt unknown
- 2016-07-29 PT PT167480235T patent/PT3328888T/pt unknown
- 2016-07-29 EP EP22203815.0A patent/EP4183805A1/en active Pending
- 2016-07-29 HU HUE16748023A patent/HUE061419T2/hu unknown
- 2016-07-29 JP JP2018504829A patent/JP6975707B2/ja active Active
- 2016-07-29 EA EA201890368A patent/EA038603B1/ru unknown
- 2016-07-29 CA CA2994245A patent/CA2994245A1/en active Pending
- 2016-07-29 MD MDE20180558T patent/MD3328888T2/ro unknown
- 2016-07-29 RS RS20230150A patent/RS63991B1/sr unknown
- 2016-07-29 US US15/223,434 patent/US10179819B2/en active Active
- 2016-08-01 AR ARP160102342A patent/AR106570A1/es unknown
-
2018
- 2018-11-23 HK HK18115045.3A patent/HK1255971A1/zh unknown
- 2018-11-30 US US16/205,917 patent/US11155633B2/en active Active
-
2021
- 2021-09-16 US US17/476,856 patent/US20210403595A1/en active Pending
- 2021-11-05 JP JP2021180839A patent/JP7271637B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MD3328888T2 (ro) | Anticorpi anti-PSMA, molecule de legare a antigenelor bispecifice care leagă PSMA și CD3 și utilizările acestora | |
MD3353212T2 (ro) | Anticorpi bispecifici anti-CD3 optimizați și utilizările acestora | |
PH12020552116A1 (en) | Bispecific anti-psma x anti-cd28 antibodies and uses thereof | |
EA201691858A1 (ru) | Композиции антител для лечения опухолей | |
EA202191580A1 (ru) | Биспецифичные антитела анти-cd28 x анти-cd22 и их применение | |
EA201992402A1 (ru) | Антитела против ilt4 и антигенсвязывающие фрагменты | |
EA201590613A1 (ru) | Антитела против cd3, биспецифические антигенсвязывающие молекулы, которые связываются с cd3 и cd20, и их применения | |
EA202092933A1 (ru) | Антитела к entpd2, виды комбинированной терапии и способы применения антител и видов комбинированной терапии | |
PH12021551238A1 (en) | Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof | |
PH12016501384B1 (en) | Human antibodies to pd-l1 | |
EA201991763A1 (ru) | Конъюгаты антитела к ccr7 и лекарственного средства | |
EA201890175A1 (ru) | Антитела к cd40 | |
MX2018008934A (es) | Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso. | |
MY189159A (en) | Multispecific antigen-binding molecules and uses thereof | |
MY176475A (en) | Human antibodies to pd-1 | |
EA201792193A1 (ru) | Конструкции биспецифического антитела для cdh3 и cd3 | |
CY1123926T1 (el) | Αντισωματα κατα της τρανσγλουταμινασης 2 | |
MX2021000783A (es) | Anticuerpos humanizados contra psma. | |
CR20200623A (es) | Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso | |
BR112022002761A2 (pt) | Proteínas de ligação a 4-1bb e ox40 e composições e métodos relacionados, anticorpos contra 4-1bb, anticorpos contra ox40 | |
MX2022005238A (es) | Tratamiento del cancer usando un anticuerpo biespecifico contra hla-a2/wt1 x cd3 y lenalidomida. | |
EA202190089A1 (ru) | Биспецифичные антитела анти-psma x анти-cd28 и их применения | |
EA202092279A1 (ru) | Антитела к mica и/или micb и их применение | |
EA202090303A3 (ru) | Композиции антител для лечения опухолей | |
EA202092151A1 (ru) | Антитела |